For the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results. A positive test of the clinical response to Duodopa® administered via a temporary nasoduodenal tube is required before a permanent tube is inserted.
|13/03/2013||16/04/2013||Full Pharmacoeconomic Evaluation Recommended.|
|26/09/2013||30/12/2013||Reimbursement not recommended at the submitted price|
The HSE has approved reimbursement following confidential price negotiations.
|The HSE has now requested a full HTA for this product 25th June 2018|
|Full pharmacoeconomic assessment commissioned by HSE||25/06/2018|
|Pre-submission consultation with Applicant||05/07/2018|
|Submission received from Applicant||10/09/2018|
|Preliminary review sent to Applicant||05/12/2018|
|NCPE assessment re-commenced||14/01/2019|
|Preliminary review II sent to Applicant||30/01/2019|
|NCPE assessment re-commenced||15/02/2019|
|Factual accuracy sent to Applicant||19/03/2019|
|NCPE assessment re-commenced||02/04/2019|
|NCPE assessment completed||14/06/2019|
|NCPE assessment outcome||The NCPE recommends that levodopa and carbidopa intestinal gel (Duodopa®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.|